JUN and breast cancer: Considering that miR10b is markedly elevated in tumor samples from patients with advanced-stage breast cancer [13, 36], pancreatic adenocarcinomas [37], and glioblastomas [38, 39], this c-Jun activating pathway might play an important part in determining the highly metastatic and invasive phenotypes of the cells.